Telmisartan in High-Risk Cardiovascular Patients
December 19th, 2009 Posted by: admin
Publication year: 2010
Source: The American Journal of Cardiology, Volume 105, Issue 1, Supplement 1, 4 January 2010, Pages 36A-43A
Michael A., Weber
Increasing attention is being devoted to the use of combination therapy with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in order to achieve maximal blockade of the renin–angiotensin system (RAS) in patients at high risk of cardiovascular events. This approach has been adopted in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET), which compared the effects of the ARB telmisartan and the ACE inhibitor ramipril, alone and in combination, on cardiovascular mortality and morbidity in high-risk patients with vascular disease or diabetes mellitus and end-organ damage. The results showed that telmisartan was as…
Similar Posts:
- Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])
- Role of Renin-Angiotensin System Blockade in Patients With Diabetes Mellitus
- Cardiovascular Events in Omalizumab Trial Prompt FDA Scrutiny
- Cardiovascular Events in Omalizumab Trial Prompt FDA Scrutiny
- Cardiovascular Events in Omalizumab Trial Prompt FDA Scrutiny
- Cardiovascular Events in Omalizumab Trial Prompt FDA Scrutiny
- Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?
- Are There Effects of Renin–Angiotensin System Antagonists Beyond Blood Pressure Control?
- Usefulness of Statin–Ezetimibe Combination to Reduce the Care Gap in Dyslipidemia Management in Patients With a High Risk of Atherosclerotic Disease
- Observed and Predicted Reduction of Ischemic Cardiovascular Events in the Simvastatin and Ezetimibe in Aortic Stenosis Trial